Get the Stockscreener App
108.19
0.87%
1.145
Jazz Pharmaceuticals Plc stock is traded at $108.19, with a volume of 42,625.
It is up +0.87% in the last 24 hours and down -0.92% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$107.05
Open:
$106.94
24h Volume:
42,625
Relative Volume:
0.04
Market Cap:
$6.84B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
15.24
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
-2.28%
1M Performance:
-0.92%
6M Performance:
-11.30%
1Y Performance:
-4.17%
1-Day Range:
$106.56
$108.14
1-Week Range:
$106.56
$111.45
52-Week Range:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
108.13 | 6.84B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.90 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.07 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.27 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.01 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Autistic Disorder Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Biosciences - Barchart.com
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav® - Insider Monkey
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®. - Yahoo Finance
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Stock Ratings Reiterated by Needham - GuruFocus
Jazz Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Nigeria
Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - marketscreener.com
Transcript : Jazz Pharmaceuticals plcSpecial Call - marketscreener.com
Jazz Pharmaceuticals Says Zepzelca-Tecentriq Combination Gets FDA Priority Review for Lung Cancer Treatment - marketscreener.com
FDA Fast-Tracks Jazz Pharmaceuticals' Lung Cancer Drug Application - GuruFocus
Jazz Pharma stock gains on FDA review for lung cancer therapy - Seeking Alpha
Jazz Pharmaceuticals (JAZZ) Awaits FDA Decision on Lung Cancer Treatment | JAZZ Stock News - GuruFocus
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer - PR Newswire
Jazz Pharmaceuticals Says Narcolepsy Drug Meets Primary Endpoint in Phase 4 Trial - marketscreener.com
Parallel Advisors LLC Acquires 119 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Jazz Pharmaceuticals (JAZZ) Reveals New Findings on Xywav at SLE - GuruFocus
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcas - GuruFocus
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 - PR Newswire
Jazz Pharmaceuticals' Xywav Achieves 4.1 mmHg Blood Pressure Reduction in Groundbreaking Phase 4 Trial - Stock Titan
Transcript : Jazz Pharmaceuticals plc Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - marketscreener.com
Jazz Pharmaceuticals misses estimates, slashes guidance on litigation costs By Investing.com - Investing.com Nigeria
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? - Yahoo Finance
May 2026 Options Now Available For Jazz Pharmaceuticals - Nasdaq
Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ) - MSN
Insider Sell: Bruce Cozadd Sells Shares of Jazz Pharmaceuticals PLC - GuruFocus
Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC - MSN
Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given “Buy” Rating at Needham & Company LLC - Defense World
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer StudyJazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga
UBS maintains buy rating on Jazz Pharmaceuticals stock after positive trial data - Investing.com Nigeria
Jazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment - MSN
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts - Benzinga
Jazz Pharmaceuticals (JAZZ) Maintains Buy Rating with $202 Price Target | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Reports Positive Results for Zepzelc - GuruFocus
Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Resu - GuruFocus
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination - marketscreener.com
Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Results for Zepzelca | JAZZ Stock News - GuruFocus
Zepzelca combo extends survival in lung cancer study - Investing.com
Phase 3 Trial: Zepzelca Combo Cuts Lung Cancer Progression Risk by 46% | JAZZ Stock News - Stock Titan
Jazz Pharmaceuticals (JAZZ) Reports Promising Long-term Data for Ziihera | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Says Ziihera Achieves Over 3 Years Median Overall Survival in Gastroesophageal Cancer - marketscreener.com
Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera - Investing.com
Jazz Pharmaceuticals (JAZZ) Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera in mGEA - StreetInsider
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 - PR Newswire
Breakthrough: Jazz's Cancer Drug Doubles Survival Time in HER2+ Gastric Cancer Trial - Stock Titan
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire Inc.
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Como - GuruFocus
Jazz Pharmaceuticals Reveals 19 New Xywav Studies for Sleep Disorders at SLEEP 2025 | JAZZ Stock News - Stock Titan
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PR Newswire
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):